-
摘要: 糖尿病是由于胰岛素分泌绝对缺乏或/和相对缺乏(包括β细胞衰变和胰岛素抵抗),胰岛素的生物效应降低(胰岛素抵抗,胰岛素敏感性降低,葡萄糖清除能力下降),引起的以慢性高血糖为特征的一组代谢病.近年来许多研究证实2型糖尿病发病前已存在胰岛素抵抗[1].胰岛素抵抗的存在不可避免地使血糖控制状况持续恶化,与之有关的多种血管并发症亦随之发生.如何预防和治疗糖尿病是当今医学界面临的重大课题,如何解决胰岛素抵抗成为人们关注的焦点.奥洛华,即盐酸罗格列酮胶囊,属噻唑烷二酮类药,是一类直接针对2型糖尿病的根本病理生理缺陷--胰岛素抵抗的新药.本文就具有改善胰岛素抵抗、增强胰岛素敏感性的新药奥洛华和传统药物二甲双胍对2型糖尿病的疗效进行了探讨比较.
-
关键词:
- 2型糖尿病 /
- 胰岛素抵抗 /
- 盐酸罗格列酮(奥洛华) /
- 二甲双胍
-
-
Haring HU, Mehert H. Pathogenesis of type 2 diabetes melli-tus;cardidates for a aignal transmitter defect causing insulinresistance of the skeletal muscle [J]. Diabetologia, 1993.176.doi: 10.1007/BF00399946. Spiegelman BM. PPAR-gamma;adipogenic regulator and thiazolidinedione receptor [J]. Diabetes, 1998, (4):507.doi: 10.2337/diabetes.47.4.507. Smith SA, Cawthome MA, Coyle PJ. BRL 49653 nor-malises glycaemic control in Zucker fa/ fa rats by improving hepatic and peripheral tissiu sensitivity to insulin [J]. Dia-betologia, 1993(1):184. Jones NP, CharbonnelB, Lonnqvist F. Rosiglitazone re-duces plasma inulin and its precursors white decreasing gly-caemia in typy 2 diabetes [J]. Diabetologia, 1999, (Suppl 1):A229. Young PW, Buckle DR, Cantello BC. Identification of high-affinity blinding sites for the insulin sensitizer rosigli-tazone(BRL-49683)in rodent and human adipocytes using a radioiodinated ligand for peroxisonmal proliferator:activated receptor gamma [J]. Journal of Pharmacology and Experimental Therapeutics, 1998(2):751.
计量
- 文章访问数: 108
- HTML全文浏览量: 16
- PDF下载量: 7
下载:
苏公网安备 32100302010246号
